Ahmed Bassam Mohd, Omar B Mohd, Yasmeen J Alabdallat, Salem Yousef Al Dwairy, Reem A Ghannam, Balqees M Hanaqtah, Khaled A Albakri
Dinutuximab, which is a monoclonal antibody targeting GD2 expressed in neuroblasts, improves survival when included in the therapy regimen. This article reviews the importance of dinutuximab in managing neuroblastoma (NB). Dinutuximab targets high levels of GD2 expression in NB cells, thus increasing event-free survival when used in the maintenance therapy of high-risk patients with NB. Although several collaborative studies have set the standard of care for maintenance therapy, the long-term follow-up and continuous evaluation of the use of antibodies and the co-administration of other pharmacological or immunomodulatory drugs remain to be studied...
2023: Journal of Research in Medical Sciences: the Official Journal of Isfahan University of Medical Sciences